A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease over a Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks
Latest Information Update: 30 May 2025
At a glance
- Drugs Darvadstrocel (Primary)
- Indications Rectal fistula
- Focus Registrational; Therapeutic Use
- Sponsors Takeda; Takeda Development Center Americas
Most Recent Events
- 25 May 2025 Status changed from active, no longer recruiting to discontinued.
- 27 Mar 2025 Planned primary completion date changed from 30 Jun 2025 to 31 Dec 2025.
- 27 Mar 2025 Status changed to active, no longer recruiting.